GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Lupus Erythematosus, Systemic, Systemic Vasculitis, Isolated Angiitis of Central Nervous System, Lung Disease With Systemic Sclerosis, Lung Disease Interstitial Diffuse

In brief

The purpose of this study it to determine whether the use of a gonadotropin releasing hormone (GnRH)-agonist (depot-leuprolide acetate) during cyclophosphamide (CYC) therapy in women with rheumatic diseases will provide greater ovarian protection than placebo.

Key facts

Study ID
NCT01257802
Run by
Joseph Mccune
People needed
14
Starts
2011-05-01
Expected to finish
2015-11-01
Last updated by the study team
2017-06-27

Who can join

Age: 18 and older, up to 40. Sex: female. Healthy volunteers: not accepted.

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.